EPIdemiological Approaches to the Cardiovascular Consequences of COVID-19

• Conditions: Acute Myocardial Infarction
• Interventions: Biological: Biological data; Other: Clinical data

• Registration Number: NCT04498091
• Lead Sponsor: Centre Hospitalier Universitaire Dijon

Brief Summary

The COVID-19 pandemic highlights the importance of the prognosis of co-morbidities, such as coronary artery disease, which significantly increase the risk of mortality in patients infected with SARS-CoV2. Investigators have recently studied the complex links between respiratory infections, particularly pneumonia, and type 2 myocardial infarction (MI) in many respects. The etiology of type 2 MI is based on an imbalance of myocardial oxygen supply/need in the absence of rupture/erosion of atheromatous plaques. Based on the RICO survey data, the investigators investigated whether COVID-19-related sepsis and/or respiratory failure could be an underlying mechanism of MI2.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-03-15
• Primary Completion: 2020-07-01
• Status Verified: 2020-08
• Study First Submitted: 2020-08-03
• Study First Submitted QC: 2020-08-03
• Last Update Submitted: 2020-08-03
• Study First Posted: 2020-08-04
• Last Update Posted: 2020-08-04
• Study Completion: 2021-07

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 35

Inclusion Criteria

• patients hospitalized for a type 2 MI in CCU from CHU Dijon Bourgogne With or without pneumonia
• patients hospitalized for a type 2 MI in CCU from CHU Dijon Bourgogne With or without COVID 19

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
C	Biological data	Type 2 MI with pneumonia without COVID-19
D	Biological data	Type 2 MI without pneumonia and without COVID-19
B	Clinical data	Type 2 without COVID-19
C	Clinical data	Type 2 MI with pneumonia without COVID-19
A	Biological data	Type 2 MI with COVID-19
B	Biological data	Type 2 without COVID-19
A	Clinical data	Type 2 MI with COVID-19
D	Clinical data	Type 2 MI without pneumonia and without COVID-19

Primary Outcome Measures

Name	Time	Method
Characterizing type 2 myocardial infarction associated with CoV-2 SARS infection	Through study completion, an average of 1 year

Trial Locations

Locations (1)

Chu Dijon Bourgogne; 🇫🇷 Dijon, France